Qrons (QRON) 10-Q 9 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 08, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Qrons Inc.
Entity Central Index Key	1,689,084
Trading Symbol	QRON
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		12,804,125

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 474,308	$ 57,767
Prepaid expenses	31,893	15,812
Total current assets	506,201	73,579
TOTAL ASSETS	506,201	73,579
Current liabilities
Accounts payable and accrued liabilities	25,986	14,141
Accounts payable and accrued liabilities - related party	1,906	1,410
Convertible note - related party, net of debt discount	13,027	6,665
Derivative liabilities	29,074	31,090
Total current liabilities	69,993	53,306
Total liabilities	69,993	53,306
Stockholders' equity
Series A Preferred Shares: $0.001 par value, authorized 10,000; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: shares authorized 100,000,000; 12,729,125 and 12,404,910 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	1,273	1,240
Additional Paid-in Capital	2,521,083	1,611,711
Accumulated deficit	(2,086,150)	(1,592,680)
Total stockholder's equity	436,208	20,273
TOTAL LIABILITIES & EQUITY	$ 506,201	$ 73,579

Condensed Balance Sheets (Unau3

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	12,729,125	12,404,910
Common stock shares, outstanding	12,729,125	12,404,910

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Net sales
Operating expenses:
Research and development expenses	40,897	776
Professional fees	21,180
General and administrative expenses	426,551	305
Total operating expenses	488,628	1,081
Income (loss) from operations	(488,628)	(1,081)
Other Income (expense)
Interest expense	(6,858)	(2,700)
Change in derivative liabilities	2,016
Other (expense)	(4,842)	(2,700)
Net (loss)	$ (493,470)	$ (3,781)
Net (loss) per common shares (basic and diluted)	$ (0.04)	$ 0
Weighted average shares outstanding Basic and diluted	12,639,078	11,528,622

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash Flows From Operating Activities
Net loss	$ (493,470)	$ (3,781)
Adjustments to reconcile net income to net cash provided from (used by) operating activities:
Stock awards recorded as advisory services	28,000
Stock options granted and recorded as administrative expenses and advisory services	381,405
Accretion of debt discount	6,362	2,500
Change in derivative liabilities	(2,016)
Changes in operating assets and liabilities:
Prepaid expenses	(16,081)
Accounts payable and accrued liabilities	11,845	1,072
Accounts payable and accrued liabilities, related party	496
Net cash provided (used by) operating activities	(83,459)	(209)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities
Cash Flows From Financing Activities
Proceeds from private placement	500,000	32,000
Financing costs		(19,590)
Proceeds from convertible note
Net cash provided from financing activities	500,000	12,410
Increase (decrease) in cash and cash equivalents	416,541	12,201
Cash at beginning of period	57,767	155,242
Cash at end of period	474,308	167,443
SUPPLEMENTAL DISCLOSURES
Interest paid
Income taxes paid

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Description of Business and Basis of Presentation [Abstract]
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and nature of business: Qrons Inc. ("Qrons" and/or the "Company") was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. Our headquarters are located at 777 Brickell Avenue, Suite 500, Miami, FL 33131. The Company is a p reclinical stage biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology could The Company's . On July 6, 2017, the board of directors and a majority of the Company's shareholders approved an amendment to the Company's Articles of Incorporation to change the name of the Company from "BioLabMart Inc." to "Qrons Inc.". On August 8, 2017, the Company filed Amended Articles of Incorporation with the State of Wyoming to effectuate such name change. Ariel Agreements On December 14, 2016, the Company entered into a license and research funding agreement ("License Agreement") with Ariel Scientific Innovations Ltd., formerly known as Ariel University R&D Co., Ltd., ("Ariel"), a wholly owned subsidiary of Ariel University, based in Ariel, Israel. Under the terms of the License Agreement, Professor Danny Baranes, the principal investigator and his research team will carry out further research relating to cell treatment with conditioned medium for neuronal tissue regeneration and repair. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty- bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding (the "Products). Under the License Agreement, the Company is required to use its best efforts to develop and commercialize the Products in accordance with development milestones set forth in the Agreement. In lieu of extending the research financing and research period under the License Agreement beyond the initial 12 months, on December 14, 2017, the Company entered into a 12-month services agreement with Ariel (the "Services Agreement") pursuant to which a team at Ariel under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of scaffold materials for the Company. On April 12, 2018, the Services Agreement was amended to provide for additional services as the Company may request. On March 6, 2018, the Company entered into an additional services agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their labs. Dartmouth Agreements On October 17, 2017, the Company entered into an option agreement with the Trustees of Dartmouth College which provides for, among other things, the grant to the Company of a one-year exclusive option to negotiate a worldwide, royalty bearing, exclusive license with Dartmouth for 3D printable materials in the field of human and animal health. During the option period, the Company agreed to use all commercially reasonable resources to evaluate the intellectual property and provide quarterly milestone reports and a commercialization plan upon exercise of the option. Pursuant to the agreement, the Company agreed to finance the prosecution of patents by Dartmouth to protect its intellectual property. Further, the agreement provides for the payment by the Company of an option fee and certain license fees and royalty payments based upon the Company's product sales, as part of a final negotiated license agreement. The Company exercised its option on March 26, 2018 to negotiate definitive license terms, as it continues further evaluation and research.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Financial Statement Presentation: The unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Fiscal year end: Use of Estimates: Cash Equivalents: Research and Development Costs: Advertising and Marketing Costs: Related parties: Stock-Based Compensation and Other Share-Based Payments: Stock Plan FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of our derivative liabilities as of March 31, 2018 and December 31, 2017: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of March 31, 2018: Liabilities Derivative liabilities $ - $ - $ 29,074 As of December 31, 2017: Liabilities Derivative liabilities $ - $ - $ 31,090 Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity" Income taxes: Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the three-month periods ended March 31, 2018 and 2017 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. In The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: March 31, 2018 March 31, 2017 52,000 562,000 Research Warrants at 3% of issued and outstanding shares 381,874 - Convertible Notes 26,906 - Series A Preferred shares 700 - 13,334 - Stock options, not yet vested 656,666 - Stock awards, not yet vested 290,000 - 1,421,480 562,000 New Accounting Pronouncements:

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2018
Going Concern [Abstract]
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date, and it has not generated revenue from operations. While the Company has recently raised proceeds it does not believe its resources will be sufficient to meet its operating and capital needs beyond the fourth quarter of 2018. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity, will always be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

Convertible Note - Related Part

Convertible Note - Related Party and Derivative Liabilities	3 Months Ended
	Mar. 31, 2018
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Convertible Note - Related Party and Derivative Liabilities	Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 28, 2017 the Company and CubeSquare amended Note 1 to extend the maturity date of the note from September 1, 2017 to September 1, 2018 under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and is due on September 27, 2018. Interest shall accrue from September 27, 2017 and shall be payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. The Company analyzed the amendment to Note 1 and Note 2 under and concluded that these two convertible debentures We estimated the fair value of the derivative on the inception dates, and subsequently, using the Black-Scholes valuation technique, adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms, and risk-free rates) that are necessary to fair value complex derivate instruments. The carrying value of these convertible notes is as follows: March 31, 2018 December 31, 2017 Face value of certain convertible notes $ 25,000 $ 25,000 (11,973 ) (18,335 ) Carrying value $ 13,027 $ 6,665 Amortization of the discount over the three months ended March 31, 2018 and 2017 totaled $6,362 and $2,500, respectively, which amounts have been recorded as interest expense. As a result of the application of ASC No. 815 in the periods ended March 31, 2018 and December 31, 2017 the fair value of the conversion feature is summarized as follows: Balance at December 31, 2017 $ 31,090 Derivative addition associated with convertible notes - Loss on change in fair value (2,016 ) Balance at March 31, 2018 $ 29,074 The fair value at the commitment and re-measurement dates for the Company's derivative liabilities were based upon the following management assumptions as of March 31, 2018 and commitment date: Commitment Date March 31, 2018 December 31, 2017 Expected dividends 0 0 0 Expected volatility 101% ~103% 95% ~ 102% 110% ~ 115% Expected term 0.92 ~ 1 year 0.42 ~0.49 year 0.67 ~0.74 year Risk free interest rate 1.33% 1.93% 1.53% ~ 1.65%

License and Research Funding Ag

License and Research Funding Agreements	3 Months Ended
	Mar. 31, 2018
License and Research Funding Agreements [Abstract]
License and Research Funding Agreements	Note 5 – License and Research Funding Agreements On December 14, 2016, the Company entered the License Agreement with Ariel. Under the terms of the License Agreement, Professor Danny Baranes, the principal investigator and his research team will carry out further research relating to cell treatment with conditioned medium for neuronal tissue regeneration and repair. The Company shall fund the research completed during the research period in the total amount of $100,000. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty- bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding (the "Products). Under the License Agreement, the Company is required to use its best efforts to develop and commercialize the Products in accordance with development milestones set forth in the Agreement. In addition, upon the occurrence of an Exit Event (as defined in the License Agreement) of the Company or of any affiliate commercializing the products, the Company is obligated to issue to Ariel an immediately exercisable warrant for that number of shares equal to 4% of the issued and outstanding shares of the Company at the time of issuance. The Company and Ariel entered into Addendum #1, effective December 13, 2017 (the "Addendum") to the License Agreement pursuant to which Ariel was permitted to exercise a portion of the warrant granted pursuant to the License Agreement. On December 13, 2017, the Company issued 119,950 shares of common stock to Ariel, representing 1% of the issued and outstanding shares of the Company on such date, and valued at $335,860. The right to the balance of the shares subject to the warrant remains subject to the terms of the License Agreement and the occurrence of an Exit Event (as described in the License Agreement). In addition, the Addendum provides that Ariel may not request a demand registration until the balance of the shares subject to the warrant is exercised. In addition to the other payments, the Company will pay Ariel upon the occurrence of the following milestone events, additional payments which shall be due within 6 months of completion of the milestone: - Upon successful clinical FDA Phase II completion - $130,000; and - Upon successful clinical FDA Phase III completion - $390,000 Upon successful development and commercialization and in recognition of the rights and licenses granted to the Company pursuant to the License Agreement, the Company will be subject to certain royalty payments as specified in the License Agreement. During the year ended December 31, 2017, the Company incurred total research and development costs of $1,179,777, which amount includes the aforementioned value of 119,950 shares of common stock at On March 6, 2018, the Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their labs area of neurologics pursuant to which the Company paid Ariel $20,580 on March 19, 2018 and will be required to pay $20,580 by August 21, 2018.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2018
Commitments [Abstract]
Commitments	Note 6 – Commitments Service Agreement with Ariel - Prof. Danny Baranes The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for five years after the term of the Services Agreement. During the year ended December 31, 2017, $17,250 was paid of which $1,438 was expensed in fiscal year 2017 and $8,625 was expensed for three months period ended March 31, 2018, and the remaining $7,187 will be expensed in a subsequent period. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. Further on April 26, 2018, the remaining installment of $17,250 was paid. (2) Service Agreement with Ariel - Dr. Gadi Turgeman On March 6, 2018, the Company entered into a service agreement for the services of Professor Gadi Turgeman and his neurobiology research team in their labs. As compensation for the services provided, the Company will pay Ariel (i) $20,580 within five business days of the execution of the Services Agreement, and (ii) $20,580 by August 21, 2018. The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for six years after the term of the Services Agreement. During the three months ended March 31, 2018, $20,580 was paid and recorded as prepaid expenses, of which $3,430 was expensed in three month period and the remaining $17,150 will be expensed in a subsequent period. As part of its ongoing program of research and development, the Company has retained distinguished scientists and other qualified individuals to advise the Company with respect to its technology and business strategy and to assist it in the research, development and analysis of the Company's technology and products. In furtherance thereof, the Company has retained certain Advisors as members of its Scientific Advisory Board as described below, and the Company and Advisors have entered into agreements with the following terms and conditions: - Scientific Advisory Board and Consulting Services - Advisor shall provide general consulting services to Company (the "Services") as a member of its Scientific Advisory Board ("SAB"). As a member of the SAB, Advisor agrees to provide the Services as follows: (a) attending meetings of the Company's SAB; (b) performing the duties of a SAB member at such meetings, as established from time to time by the mutual agreement of the Company and the SAB members, including without limitation meeting with Company employees, consultants and other SAB members, reviewing goals of the Company and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and improvements in the Company's scientific research and product development activities; and (c) providing consulting services to Company at its request, including a reasonable amount of informal consultation over the telephone or otherwise as requested by Company. Advisor's consultation with Company will involve services as scientific, technical and business advisor to the Company and its senior team as needed with respect to the field of neuronal injuries and neuro degenerative diseases ("the "Field") and requires the application of unique, special and extraordinary skills and knowledge that Advisor possesses in the Field. - SAB Consulting Compensation On November 15, 2017, the Company entered into Agreements with three Advisors under the terms of which two Advisors are granted the option under the 2016 Stock Option and Award Plan to purchase 20,000 shares of common stock under certain vesting terms and one Advisor under the 2016 Stock Option and Award Plan is granted an option to purchase 30,000 shares of common stock under certain vesting terms. The Company recorded stock-based compensation in the amount of $29,000 in respect to these options grants during fiscal 2017 which amount has been allocated as advisory services as part of general and administrative expenses. ( Note 8 – Stock Plan) (4) Advisory Board Agreement On January 23, 2018, the Company entered into a one-year advisory board member consulting agreement with Pavel Hilman, the controlling shareholder of Conventus Holdings SA, a BVI corporation ("Conventus"), under which Mr. Hilman will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board

Stock Plan

Stock Plan	3 Months Ended
	Mar. 31, 2018
Stock Plan [Abstract]
Stock Plan	Note 7 – Stock Plan 2016 Stock Option and Stock Award Stock Award: On December 14, 2016, the Board awarded to each of its Science Advisors, Prof. Danny Baranes and Dr. Liat Hammer, a total of 440,000 shares of common stock of which 150,000 shares vested on December 14, 2016, 145,000 shares vested on December 14, 2017, and 145,000 shares will vest on December 14, 2018, provided such advisors are still providing services to the Company. The value of the vested awards had been recorded as research and development expenses in the respective periods. A total of 290,000 stock awards are expected to vest during fiscal 2018. On January 23, 2018, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan. For the three months ended March 31, For years ended December 31, 2018 2017 2016 10,000 290,000 300,000 Fair market value per share $ 2.80 $ 2.80 $ 0.1867 Stock based compensation recognized $ 28,000 $ 812,000 $ 56,000 Stock Options: (a) Stock Options granted to Science Advisors: On November 15, 2017, under the 2016 Stock Option and Award Plan , the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company. On November 15, 2017, under the 2016 Stock Option and Award Plan , the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company. During the year ended December 31, 2017, total recognized compensation in respect of the above stock option compensation was $29,000, which amount has been allocated as advisory services as part of general and administrative expenses. During the three months ended March 31, 2018, total recognized compensation in respect of the above stock option compensation was $27,975, which amount has been allocated as advisory services as part of general and administrative expenses. As of March 31, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $107,255. (b) Stock Options granted to Officers: On December 4, 2017, the Board granted five-year option awards to each of its two officers . Option awards are granted with an exercise price of $2 at the date of grant; and vest on December 4, 2018, expiring on December 4, 2022. During the year ended December 31, 2017, total recognized compensation of $106,029 was recorded as general and administrative expenses. During the three months ended March 31, 2018, total recognized compensation of $353,430 was recorded as general and administrative expenses. As of March 31, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $954,261. using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 114.69 ~ 126.34% Risk-free interest rate 1.79% ~ 2.15% Expected life (years) 3 ~ 5 Stock Price $ 2.80 Exercise Price $ 0.40 ~ 2.00 A summary of the activity for the Company's stock options for the period ended March 31, 2018 and for the year ended December 31, 2017, is as follows: March 31, 2018 December 31, 2017 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 670,000 $ 1.93 - $ - Granted - $ - 670,000 $ 1.93 Exercised - $ - - $ - Canceled - $ - - $ - Outstanding, end of period 670,000 $ 1.93 670,000 $ 1.93 Options exercisable, end of period 13,334 $ 2.00 13,334 $ 2.00 Options expected to vest, end of period 656,666 $ 1.89 656,666 $ 1.89 Weighted average fair value of options granted $ 2.36 $ 2.36

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2018
Capital Stock [Abstract]
Capital Stock	Note 8 – Capital Stock Authorized: The Company has authorized 100,000,000 shares of common stock, $0.0001 par value and 10,000 shares of a class of preferred stock called the "Series A Preferred Stock", par value $0.001. Series A Preferred Stock: Each share of Series A Preferred Stock has a stated value of $1 per share and accrues 4% per annum for determination of liquidation, conversion or redemption. The shares convert at the option of the holder into shares of common stock at the market value of the common stock. The Series A Preferred Stock vote as a single class and maintain 66 2/3% of the total votes as long as any shares of Series A Preferred Stock remain outstanding. The Series A Preferred Stock contains liquidation preference (senior rank to all common) and are not to be amended without the holders' approval. At inception on August 22, 2016, the Company approved the issuance of 1,000 shares of Series A Preferred Stock at par value to Jonah Meer, the Company's Chief Executive Officer, Chief Financial Officer and Secretary, for cash $1 was paid for the Series A Preferred Stock. Common Stock issuances during the three months ended March 31, 2018: On January 23, 2018 the Company sold 312,500 shares of its common stock to Conventus and raised $500,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes. On January 23, 2018, the Company issued 10,000 shares for advisory services (Note 6(4)). On February 6, 2018, the Company shares of common stock Common Stock issuances as of December 31, 2017: On December 13, 2017, 119,950 shares were issued to Ariel as an exercise of warrants pursuant to a License Agreement (Note 5 – License and Research Funding Agreement). These shares were valued at $335,860 or $2.80 per share, based on fair market value, and the associated cost was recorded as research and development expenses. On December 14, 2017, the Company issued 290,000 shares to two Scientific Advisors as a stock award, During the year ended December 31, 2017, the Company received aggregate proceeds of $32,000 in private placement subscriptions for a total of 128,000 shares. During the year ended December 31, 2017 the Company shares of common stock Share Purchase Warrants In accordance with authoritative accounting guidance, the fair value of the aforementioned warrants was calculated using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 97.90~119.33% Risk-free interest rate 1.47~1.60% Expected life (years) 2.71~2.92 Stock Price $ 0.25 Exercise Price $ 0.40 As of March 31, 2018, and December 31, 2017, the following common stock purchase warrants were outstanding: Warrants (1) Weighted Average Exercise Price Outstanding – December 31, 2016 502,000 $ 0.40 Granted 64,000 0.40 Forfeited/Canceled - - Exercised 512,000 (2) 0.40 Outstanding – December 31, 2017 54,000 0.40 Granted - - Forfeited/Canceled - - Exercised 2,000 (3) 0.40 Outstanding – March 31, 2018 52,000 $ 0.40 (1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40. (2) During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis. (3) During the three-month period ended March 31, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events On April 12, 2018, the Company amended its services agreement, dated December 12, 2017 with Ariel Scientific Innovations Ltd. The Amendment provides for the payment of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. All other terms and conditions of the Services Agreement remain in effect. On April 16, 2018, the Company entered into a one-year advisory board member consulting agreement with Chenfeng Ke, Assistant Professor of Chemistry at of Dartmouth College, pursuant to which Professor Ke will serve on the Company's Scientific Advisory Board. In consideration for serving on the Scientific Advisory Board, the Company granted an option to purchase 30,000 shares of its common stock to Professor Ke. On April 23, 2018, the Company entered into a six-month investment relations agreement with an investor relations firm for a monthly consulting fee of $5,000 and issued 75,000 shares of its common stock as commitment shares for agreeing to enter into such agreement.

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Summary of Significant Accounting Policies [Abstract]
Financial Statement Presentation	Financial Statement Presentation: The unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").
Fiscal year end	Fiscal year end:
Use of Estimates	Use of Estimates:
Cash Equivalents	Cash Equivalents:
Research and Development Costs	Research and Development Costs:
Advertising and Marketing Costs	Advertising and Marketing Costs:
Related parties	Related parties:
Stock-Based Compensation and Other Share-Based Payments	Stock-Based Compensation and Other Share-Based Payments: Stock Plan
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of our derivative liabilities as of March 31, 2018 and December 31, 2017: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of March 31, 2018: Liabilities Derivative liabilities $ - $ - $ 29,074 As of December 31, 2017: Liabilities Derivative liabilities $ - $ - $ 31,090
Warrants	Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity"
Income taxes	Income taxes:
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the three-month periods ended March 31, 2018 and 2017 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. In The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: March 31, 2018 March 31, 2017 52,000 562,000 Research Warrants at 3% of issued and outstanding shares 381,874 - Convertible Notes 26,906 - Series A Preferred shares 700 - 13,334 - Stock options, not yet vested 656,666 - Stock awards, not yet vested 290,000 - 1,421,480 562,000
New Accounting Pronouncements	New Accounting Pronouncements:

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Summary of Significant Accounting Policies [Abstract]
Schedule of fair value of derivative liabilitie measurements on recurring basis	Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of March 31, 2018: Liabilities Derivative liabilities $ - $ - $ 29,074 As of December 31, 2017: Liabilities Derivative liabilities $ - $ - $ 31,090
Schedule of potentially dilutive securities	March 31, 2018 March 31, 2017 52,000 562,000 Research Warrants at 3% of issued and outstanding shares 381,874 - Convertible Notes 26,906 - Series A Preferred shares 700 - 13,334 - Stock options, not yet vested 656,666 - Stock awards, not yet vested 290,000 - 1,421,480 562,000

Convertible Note - Related Pa17

Convertible Note - Related Party and Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Schedule of convertible notes	March 31, 2018 December 31, 2017 Face value of certain convertible notes $ 25,000 $ 25,000 (11,973 ) (18,335 ) Carrying value $ 13,027 $ 6,665
Schedule of fair value of conversion feature	Balance at December 31, 2017 $ 31,090 Derivative addition associated with convertible notes - Loss on change in fair value (2,016 ) Balance at March 31, 2018 $ 29,074
Schedule of fair value at commitment and re-measurement dates derivative liabilities	Commitment Date March 31, 2018 December 31, 2017 Expected dividends 0 0 0 Expected volatility 101% ~103% 95% ~ 102% 110% ~ 115% Expected term 0.92 ~ 1 year 0.42 ~0.49 year 0.67 ~0.74 year Risk free interest rate 1.33% 1.93% 1.53% ~ 1.65%

Stock Plan (Tables)

Stock Plan (Tables)	3 Months Ended
	Mar. 31, 2018
Stock Plan [Abstract]
Schedule of stock award	For the three months ended March 31, For years ended December 31, 2018 2017 2016 10,000 290,000 300,000 Fair market value per share $ 2.80 $ 2.80 $ 0.1867 Stock based compensation recognized $ 28,000 $ 812,000 $ 56,000
Schedule of fair value options assumptions	Measurement date Dividend yield 0% Expected volatility 114.69 ~ 126.34% Risk-free interest rate 1.79% ~ 2.15% Expected life (years) 3 ~ 5 Stock Price $ 2.80 Exercise Price $ 0.40 ~ 2.00
Schedule of stock options	March 31, 2018 December 31, 2017 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 670,000 $ 1.93 - $ - Granted - $ - 670,000 $ 1.93 Exercised - $ - - $ - Canceled - $ - - $ - Outstanding, end of period 670,000 $ 1.93 670,000 $ 1.93 Options exercisable, end of period 13,334 $ 2.00 13,334 $ 2.00 Options expected to vest, end of period 656,666 $ 1.89 656,666 $ 1.89 Weighted average fair value of options granted $ 2.36 $ 2.36

Capital Stock (Tables)

Capital Stock (Tables)	3 Months Ended
	Mar. 31, 2018
Capital Stock [Abstract]
Schedule of fair value warrants assumptions	Measurement date Dividend yield 0% Expected volatility 97.90~119.33% Risk-free interest rate 1.47~1.60% Expected life (years) 2.71~2.92 Stock Price $ 0.25 Exercise Price $ 0.40
Schedule of common stock purchase warrants were outstanding	Warrants (1) Weighted Average Exercise Price Outstanding – December 31, 2016 502,000 $ 0.40 Granted 64,000 0.40 Forfeited/Canceled - - Exercised 512,000 (2) 0.40 Outstanding – December 31, 2017 54,000 0.40 Granted - - Forfeited/Canceled - - Exercised 2,000 (3) 0.40 Outstanding – March 31, 2018 52,000 $ 0.40 (1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40. (2) During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis. (3) During the three-month period ended March 31, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Level 1 [Member]
Liabilities
Derivative liabilities
Level 2 [Member]
Liabilities
Derivative liabilities
Level 3 [Member]
Liabilities
Derivative liabilities	$ 29,074	$ 31,090

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Details 1) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	1,421,480	562,000
Stock options, vested
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	13,334
Stock options, not yet vested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	656,666
Stock awards, not yet vested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	290,000
Series A Preferred shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	700
Stock purchase warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	52,000	562,000
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	26,906
Research Warrrants at 3% of issued and outstanding shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	381,874

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Summary of Significant Accounting Policies (Textual)
Research and development costs	$ 40,897	$ 776
Advertising or marketing costs	$ 5,000
Research warrants issued and outstanding, percentage	3.00%

Convertible Note - Related Pa23

Convertible Note - Related Party and Derivative Liabilities (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Face value of certain convertible notes	$ 25,000	$ 25,000
Less: unamortized discount	(11,973)	(18,335)
Carrying value	$ 13,027	$ 6,665

Convertible Note - Related Pa24

Convertible Note - Related Party and Derivative Liabilities (Details 1)	3 Months Ended
	Mar. 31, 2018USD ($)
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Balance at December 31, 2016	$ 31,090
Derivative addition associated with convertible notes
Loss on change in fair value	(2,016)
Balance at December 31, 2017	$ 29,074

Convertible Note - Related Pa25

Convertible Note - Related Party and Derivative Liabilities (Details 2)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Derivative [Line Items]
Expected dividends	0.00%	0.00%
Risk free interest rate	1.93%
Commitment Date [Member]
Derivative [Line Items]
Expected dividends	0.00%
Risk free interest rate	1.33%
Minimum [Member]
Derivative [Line Items]
Expected volatility	95.00%	110.00%
Expected term	5 months 1 day	8 months 2 days
Risk free interest rate		1.53%
Minimum [Member] | Commitment Date [Member]
Derivative [Line Items]
Expected volatility	101.00%
Expected term	11 months 1 day
Maximum [Member]
Derivative [Line Items]
Expected volatility	102.00%	115.00%
Expected term	5 months 27 days	8 months 26 days
Risk free interest rate		1.65%
Maximum [Member] | Commitment Date [Member]
Derivative [Line Items]
Expected volatility	103.00%
Expected term	1 year

Convertible Note - Related Pa26

Convertible Note - Related Party and Derivative Liabilities (Details Textual) - USD ($)	Sep. 27, 2017	Sep. 01, 2016	Mar. 31, 2018	Mar. 31, 2017
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling
Amortization of discount			$ 6,362	$ 2,500
CubeSquare, LLC [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling	$ 15,000	$ 10,000
Interest rate per annum	8.00%	8.00%
Conversion, description	Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare.	(i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender.
Maturity date		Sep. 1, 2017
Maturity date, description	Note 1 to extend the maturity date of the note from September 1, 2017 to September 1, 2018 under the same terms and conditions.
CubeSquare, LLC [Member] | President [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Ownership percentage		25.00%

License and Research Funding 27

License and Research Funding Agreements (Details) - USD ($)	Mar. 06, 2018	Dec. 13, 2017	Dec. 14, 2016	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
License and Research Funding Agreements (Textual)
Research and development costs				$ 40,897	$ 776
License and research funding agreement compensation paid, description	The Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their labs area of neurologics pursuant to which the Company paid Ariel $20,580 on March 19, 2018 and will be required to pay $20,580 by August 21, 2018.			The Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.
Ariel University [Member]
License and Research Funding Agreements (Textual)
Shares issued for advisory services		119,950
Shares issued, value		$ 335,860
Shares issued, percentage		1.00%
License Agreement [Member]
License and Research Funding Agreements (Textual)
Total amount of fund for research during research period			$ 100,000
Warrant exercisable percentage			4.00%
Payments of completion of milestone events, description			· Upon successful clinical FDA Phase II completion - $130,000; and · Upon successful clinical FDA Phase III completion - $390,000
Research and development costs						$ 1,179,777
Aforementioned funding amount						119,950
Stock based compensation						812,000
Payments of completion of milestone events due			6 months
Shares issued, value						$ 335,860

Commitments (Details)

Commitments (Details) - USD ($)	Apr. 12, 2018	Jan. 23, 2018	Nov. 15, 2017	Mar. 31, 2018	Dec. 31, 2017	May 01, 2018	Mar. 06, 2018	Dec. 14, 2017
Commitments (Textual)
Compensation for the services provided					$ 17,250
Compensation cost					1,438
Expensed in subsequent payment				$ 31,893	15,812
Prepaid expenses				20,580
Prepaid expensed during period				3,430
Outstanding expenses				17,150
Service Agreement With Ariel [Member]
Commitments (Textual)
Compensation for the services provided							$ 20,580	$ 17,250
Compensation cost				8,625	$ 7,187
Expensed in subsequent payment				$ 7,187			$ 20,580
2016 Stock Option and Award Plan [Member]
Commitments (Textual)
Advisors are granted the option		10,000	20,000
Stock option and award plan is granted			30,000
Stock based compensation			$ 29,000
Subsequent Events [Member]
Commitments (Textual)
Compensation for the services provided						$ 17,250
Service agreement payment, description	The Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. Further on April 26, 2018, the remaining installment of $17,250 was paid.

Stock Plan (Details)

Stock Plan (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Stock Plan [Abstract]
Number of shares issued	10,000	290,000	300,000
Fair market value per share	$ 2.80	$ 2.80	$ 0.1867
Stock based compensation recognized	$ 28,000	$ 812,000	$ 56,000

Stock Plan (Details 1)

Stock Plan (Details 1) - Stock Options [Member] - Measurement date [Member]	3 Months Ended
	Mar. 31, 2018$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Stock Price	$ 2.80
Exercise Price, Minimum	0.40
Exercise Price, Maximum	$ 2
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	114.69%
Risk-free interest rate	1.79%
Expected life (years)	3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	126.34%
Risk-free interest rate	2.15%
Expected life (years)	5 years

Stock Plan (Details 2)

Stock Plan (Details 2) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Stock Plan [Abstract]
Shares Outstanding, beginning of period	670,000
Shares, Granted		670,000
Shares, Exercised
Shares, Canceled
Shares Outstanding, end of period	670,000	670,000
Shares Options exercisable, end of period	13,334	13,334
Shares, Options expected to vest, end of period	656,666	656,666
Weighted Average Shares Exercise Price, Outstanding, beginning of period	$ 1.93
Weighted Average Shares Exercise Price, Granted		1.93
Weighted Average Shares Exercise Price, Exercised
Weighted Average Exercise Price, Canceled
Weighted Average Shares Exercise Price, Outstanding, end of period	1.93	1.93
Weighted Average Exercise Price, Options exercisable, end of period	2	2
Weighted Average Exercise Price, Options expected to vest, end of period	1.89	1.89
Weighted Average Exercise Price, Weighted average fair value of options granted	$ 2.36	$ 2.36

Stock Plan (Details Textual)

Stock Plan (Details Textual) - USD ($)	Dec. 14, 2017	Dec. 04, 2017	Dec. 14, 2016	Nov. 15, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Jan. 23, 2018
Stock Plan (Textual)
Stock purchase warrants					1,421,480	562,000
Stock option vested and recorded as consulting fees							$ 29,000
Total unrecognized compensation remaining to be recognized in future periods					$ 107,255
Shares issued upon grant date							670,000
Stock options granted and recorded as administrative expenses and advisory services					$ 381,405
General and administrative expenses							$ 106,029
2016 Stock Option and Award Plan [Member]
Stock Plan (Textual)
Reserved shares for issuance			10,000,000
Stock award									10,000
Description of services agreement				Under the 2016 Stock Option and Award Plan , the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company.
Stock options granted and recorded as administrative expenses and advisory services					27,975
2016 Stock Option and Award Plan one [Member]
Stock Plan (Textual)
Description of services agreement				Under the 2016 Stock Option and Award Plan , the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company.
Total unrecognized compensation remaining to be recognized in future periods					954,261
Stock options granted and recorded as administrative expenses and advisory services					$ 353,430
Board of Directors Chairman [Member]
Stock Plan (Textual)
Stock award			440,000
Receive common stock vest upon grant date			150,000
Vested shares	145,000		145,000
Weighted average exercise pric		$ 2
Shares of common stock under certain vesting terms		5 years
Grant date		Dec. 4, 2022
Board of Directors Chairman [Member] | December 14, 2018 [Member]
Stock Plan (Textual)
Vested shares					145,000
Stock awards, not yet vested [Member]
Stock Plan (Textual)
Stock purchase warrants					290,000

Capital Stock (Details)

Capital Stock (Details) - Measurement date [Member] - Stock Purchase Warrants [Member]	3 Months Ended
	Mar. 31, 2018$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Stock Price	$ 0.25
Exercise Price	$ 0.40
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	119.33%
Risk-free interest rate	1.60%
Expected life (years)	2 years 11 months 1 day
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	97.90%
Risk-free interest rate	1.47%
Expected life (years)	2 years 8 months 16 days

Capital Stock (Details 1)

Capital Stock (Details 1) - Stock Purchase Warrants [Member] - $ / shares		3 Months Ended		12 Months Ended
		Mar. 31, 2018		Dec. 31, 2017
Warrants
Outstanding - Beginning balance	[1]	54,000		502,000
Granted	[1]			64,000
Forfeited/Canceled	[1]
Exercised	[1]	2,000	[2]	512,000	[3]
Outstanding - Ending balance	[1]	52,000		54,000
Weighted Average Exercise Price
Outstanding - Beginning balance		$ 0.40		$ 0.40
Granted				0.40
Forfeited/Canceled
Exercised		0.40		0.40
Outstanding - Ending balance		$ 0.40		$ 0.40
[1]	Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.
[2]	During the three-month period ended March 31, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.
[3]	During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis.

Capital Stock (Details Textual)

Capital Stock (Details Textual) - USD ($)

Feb. 06, 2018

Jan. 23, 2018

Dec. 14, 2017

Dec. 13, 2017

Dec. 04, 2017

Dec. 14, 2016

Mar. 31, 2018

Aug. 22, 2016

Dec. 31, 2017

Capital Stock (Textual)

Common stock, shares authorized

100,000,000

100,000,000

Common stock, par value

$ 0.0001

$ 0.0001

Common stock issued

12,729,125

12,404,910

Common stock shares, outstanding

12,729,125

12,404,910

Preferred stock, shares issued

2,000

2,000

Preferred stock, shares authorized

10,000

10,000

Preferred stock, par value

$ 0.001

$ 0.001

General and administrative expenses

$ 106,029

Subscriptions shares

128,000

Shares issued upon grant date

670,000

Grant exercise price

$ 1.89

$ 1.89

Warrant, description

The Company received a warrant exercise notice in respect of 2,000 warrants from a subscriber and issued 1,715 shares of common stock on a cashless exercise basis as per the cashless exercise formula contained in the warrant.

Warrants received underlying shares for exercise on a cashless basis

442,960

Stock options granted, terms

The Board granted five-year option awards to each of its two officers for the purchase of 300,000 shares of the common stock of the Company. Option awards are granted with an exercise price of $2 at the date of grant; and vest on December 4, 2018, expiring on December 4, 2022.

License Agreement Terms [Member]

Capital Stock (Textual)

Share issued for agreement

119,950

Conversion value

$ 335,860

Conversion of stock par value

$ 2.80

Investors [Member]

Capital Stock (Textual)

Warrant exercise

2,000

Warrants received underlying shares for exercise on a cashless basis

1,715

Board of Directors [Member]

Capital Stock (Textual)

Stock award

440,000

Vested shares

145,000

145,000

Grant date

Dec. 4, 2022

Receive common stock vest upon grant date

150,000

Scientific Advisors [Member]

Capital Stock (Textual)

Share issued for agreement

290,000

Conversion value

$ 812,000

Conversion of stock par value

$ 2.80

Private Placement [Member]

Capital Stock (Textual)

Shares issued for advisory services

10,000

Sale and issuance of common stock

312,500

Total proceeds of subscriptions amount

$ 500,000

$ 32,000

Warrant [Member]

Capital Stock (Textual)

Warrant exercise

[2]

2,000

[1]

512,000

[3]

Series A Preferred Stock [Member]

Capital Stock (Textual)

Preferred stock, conversion basis, description

Each share of Series A Preferred Stock has a stated value of $1 per share and accrues 4% per annum for determination of liquidation, conversion or redemption. The shares convert at the option of the holder into shares of common stock at the market value of the common stock. The Series A Preferred Stock vote as a single class and maintain 66 2/3% of the total votes as long as any shares of Series A Preferred Stock remain outstanding.

Series A Preferred Stock [Member] | Jonah Meer [Member]

Capital Stock (Textual)

Preferred stock, shares issued

1,000

Cash paid

$ 1

[1]

During the three-month period ended March 31, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.

[2]

Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.

[3]

During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis.

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Events [Member]	Apr. 23, 2018USD ($)shares	Apr. 16, 2018shares	Apr. 12, 2018ILS (₪)
Services Agreement [Member]
Subsequent Events (Textual)
Compensation expenses | ₪			₪ 8,000
Advisory Board Member Consulting Agreement [Member]
Subsequent Events (Textual)
Term of agreement		1 year
Options granted to purchase of common stock		30,000
Investment Relations Agreement [Member]
Subsequent Events (Textual)
Term of agreement	6 months
Payments to investors | $	$ 5,000
Common stock shares issued	75,000